Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435187 | 0.90 | GRIK1 (0.35) | GRIK1GRIK2 | |
| SCHEMBL3092130 | 0.84 | GRIK1 (0.48) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11257659 | 0.81 | GRIK1 (0.31) | GRIK1GRIK2 | |
| SCHEMBL7550733 | 0.81 | GRIK1 (0.39) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8847417 | 0.79 | GRIK1 (0.38) | GRIK1GRIK2 | |
| SCHEMBL8847435 | 0.79 | GRIK1 (0.38) | GRIK1GRIK2 | |
| SCHEMBL8808086 | 0.78 | ACHE (0.34) | — | |
| SCHEMBL9023602 | 0.76 | ALDH1A1 (0.39) | — | |
| SCHEMBL8847232 | 0.76 | GRIK1 (0.36) | GRIK1GRIK2 | |
| SCHEMBL8847250 | 0.76 | GRIK1 (0.36) | GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | GRIK1 4259/4885GRIK2 4543/4885SLC1A3 4116/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | GRIK1 3480/4885GRIK2 3663/4885SLC1A3 4386/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | GRIK1 4259/4885GRIK2 4543/4885SLC1A3 4116/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | GRIK1 3480/4885GRIK2 3663/4885SLC1A3 4386/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | GRIK1 2911/4885GRIK2 2718/4885SLC1A3 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.